Boston Scientific (BSX) knew of pacemaker battery issues for years, NYT reports; issues linked to at least 7 deaths and 800+ injuries

This report suggests significant regulatory and reputational risks for Boston Scientific, given the longstanding knowledge of pacemaker battery issues that have reportedly resulted in fatalities and injuries. Investors should consider how this might impact BSX's stock price, potential legal ramifications, and scrutiny from regulatory bodies, which could lead to increased costs or limitations on sales strategies in the health care equipment sector.